Citigroup’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Citigroup’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,146	Closed	-$14.1K	–	6047
2022 Q4	$14.1K	Sell	1,146 -1,409	-55%	-$33.6K	﹤0.01%	4722
2022 Q3	$84K	Buy	2,555 +1,276	+100%	+$36.1K	﹤0.01%	4173
2022 Q2	$24K	Buy	1,279 +259	+25%	+$4.96K	﹤0.01%	4905
2022 Q1	$18K	Buy	+1,020	New	+$20.9K	﹤0.01%	5228

Citigroup's CINC Position: Q1 2023 in Review

Citigroup sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 1,146 shares — an estimated $14.1K sold.

Citigroup first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $84K in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

Citigroup reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citigroup sold 1,146 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $14.1K.
Citigroup first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Citigroup's CinCor Pharma, Inc. Common Stock position peaked at $84K in Q3 2022.
0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.